<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(d)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
SYNERGEN, INC.
(NAME OF SUBJECT COMPANY)
AMGEN ACQUISITION SUBSIDIARY, INC.
AMGEN INC.
(BIDDER)
COMMON STOCK, $.01 PAR VALUE
(TITLE OF CLASS OF SECURITIES)
871594107
(CUSIP NUMBER OF CLASS OF SECURITIES)
------------------------
MARGARET VALEUR-JENSEN, PH.D.
SENIOR COUNSEL
AMGEN INC.
AMGEN CENTER
1840 DEHAVILLAND DRIVE
THOUSAND OAKS, CA 91320-1789
TELEPHONE: (805) 447-1000
(NAME, ADDRESS AND TELEPHONE NUMBER OF
PERSONS AUTHORIZED TO RECEIVE NOTICES
AND COMMUNICATIONS ON BEHALF OF BIDDER)
------------------------
COPY TO:
GEORGE A. VANDEMAN, ESQ.
LATHAM & WATKINS
633 WEST FIFTH STREET, SUITE 4000
LOS ANGELES, CALIFORNIA 90071
TELEPHONE: (213) 485-1234
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
14D-1
CUSIP NO. 871594107
<TABLE>
<C> <S> <C>
- ----------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
AMGEN ACQUISITION SUBSIDIARY, INC.
- ----------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /
- ----------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ----------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS
AF
- ----------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) / /
- ----------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- ----------------------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
23,919,202 SHARES OF COMMON STOCK
- ----------------------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7)
EXCLUDES CERTAIN SHARES / /
- ----------------------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
91.2%
- ----------------------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON
CO
- ----------------------------------------------------------------------------------------------
</TABLE>
2
<PAGE> 3
14D-1
CUSIP NO. 871594107
<TABLE>
<C> <S> <C>
- ----------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
AMGEN INC.
- ----------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /
- ----------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ----------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
- ----------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) / /
- ----------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- ----------------------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
23,919,202 SHARES OF COMMON STOCK
- ----------------------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES
CERTAIN SHARES / /
- ----------------------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
91.2%
- ----------------------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON
CO
- ----------------------------------------------------------------------------------------------
</TABLE>
3
<PAGE> 4
TENDER OFFER
Amgen Acquisition Subsidiary, Inc., a Delaware corporation ("Purchaser")
and Amgen Inc., a Delaware corporation ("Parent") hereby amend and supplement
their Tender Offer Statement on Schedule 14D-1 (the "Statement") originally
filed on November 23, 1994, as amended by Amendment No. 1 filed on December 2,
1994, Amendment No. 2 filed on December 14, 1994, and Amendment No. 3 filed on
December 19, 1994, with respect to Purchaser's offer to purchase all outstanding
shares of Common Stock, par value $.01 per share (the "Shares"), of Synergen,
Inc., a Delaware corporation (the "Company"), including the associated preferred
stock purchase rights (all references to "Shares" shall include a reference to
such rights) at a price of $9.25 per share, net to the seller in cash, upon the
terms and subject to the conditions set forth in Purchaser's Offer to Purchase
dated November 23, 1994 and in the related Letter of Transmittal (which together
constitute the "Offer"). The Offer expired at midnight, New York City time, on
Wednesday, December 21, 1994. At the expiration of the Offer, based on a
preliminary count by the depositary, 23,919,202 Shares (representing
approximately 91.2% of the outstanding Shares) had been tendered pursuant to the
Offer. This amendment constitutes Purchaser's and Parent's final amendment to
the Statement pursuant to General Instruction D of Schedule 14D-1.
ITEM 5. PURPOSE OF THE TENDER OFFER AND PLANS OR PROPOSALS OF THE BIDDER
(c) Upon consummation of the merger of Purchaser into the Company, all
pre-merger officers of the Company will be removed and replaced with the
following officers of Parent, for the positions indicated: (a) N. Kirby
Alton -- Senior Vice President, Development, (b) Robert S. Attiyeh -- Senior
Vice President, Finance and Corporate Development, (c) Daniel Vapnek -- Senior
Vice President, Research, (d) Michael Bevilacqua -- Vice President, Inflammation
and Medicinal Chemistry, (e) Gordon M. Binder -- Chief Executive Officer, (f)
Kevin W. Sharer -- President and Chief Operating Officer and (g) Thomas E.
Workman, Jr. -- Vice President, Secretary and General Counsel.
ITEM 6. INTEREST IN SECURITIES OF THE SUBJECT COMPANY
(a)-(b) Based on a preliminary count by the depositary, 23,919,202 Shares
(representing approximately 91.2% of the outstanding Shares) had been tendered
to Purchaser pursuant to the Offer which expired at midnight New York City
time on Wednesday, December 21, 1994. Purchaser has accepted and will pay for,
in accordance with the terms of the Offer, all of the Shares validly tendered.
Parent may be deemed to beneficially own the Shares accepted for payment by
Purchaser because Purchaser is a wholly owned subsidiary of Parent.
ITEM 10. ADDITIONAL INFORMATION.
(a) Parent may enter into a six month consulting contract with Greg Abbott,
the current Chief Executive Officer of the Company, following completion of the
merger between Purchaser and the Company. Mr. Abbott would be paid approximately
$125,000 pursuant to such contract.
(f) The information set forth in Exhibit 99.(a)(16) is incorporated herein
by this reference.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
99.(a)(16) Press Release issued by Parent on December 22, 1994.
4
<PAGE> 5
SIGNATURE
After due inquiry and to the best of the undersigned's knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, correct and complete.
AMGEN ACQUISITION SUBSIDIARY, INC.
By /s/ Thomas E. Workman, Jr.
---------------------------------
Chief Executive Officer
Dated: December 22, 1994
5
<PAGE> 6
SIGNATURE
After due inquiry and to the best of the undersigned's knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, correct and complete.
AMGEN INC.
By /s/ Gordon M. Binder
---------------------------------
Chief Executive Officer and
Chairman of the Board
Dated: December 22, 1994
6
<PAGE> 7
EXHIBIT INDEX
<TABLE>
<CAPTION>
SEQUENTIALLY
EXHIBIT NUMBERED
NUMBER DESCRIPTION PAGE
------- ----------- ------------
<S> <C> <C>
99.(a)(16) Press Release issued by Parent on December 22, 1994...................
</TABLE>
<PAGE> 1
AMGEN ANNOUNCES SUCCESS OF
TENDER OFFER FOR SYNERGEN
<TABLE>
<S> <C>
Investor Contact: Media Contact:
Sarah H. Crampton David Kaye
Director, Investor Relations and Manager, Product
Corporate Communications Communications
(805) 447-1659 (805) 447-6692
</TABLE>
FOR IMMEDIATE RELEASE
Thousand Oaks, Calif., December 22, 1994 -- Amgen today announced that it
has successfully completed its cash tender offer for the outstanding shares of
common stock of Synergen, Inc. at $9.25 per share.
The tender offer by Amgen's wholly owned subsidiary expired at midnight EST
on December 21, 1994.
Amgen has been informed by the depositary for the tender offer that, as of
midnight EST Wednesday, December 21, 1994 and based upon a preliminary count,
approximately 91% of the outstanding shares of common stock of Synergen had been
tendered and not withdrawn. Amgen has accepted and will pay for, in accordance
with the terms of the offer, all of the shares validly tendered.
As previously announced, any shares of Synergen's common stock not tendered
and purchased pursuant to the offer will be acquired in a subsequent merger
transaction at the same $9.25 per share cash price. It is anticipated that the
merger will be effected as promptly as possible.
Amgen (NASDAQ:AMGN) is a global biotechnology company that discovers,
develops, manufactures and markets human therapeutics based on advanced cellular
and molecular biology.
